Cargando…

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been incorporated in ovarian cancer treatment in combination with chemotherapy both in a frontline setting and in disease recurrence. However, re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liontos, Michalis, Lykka, Maria, Dimopoulos, Meletios-Athanasios, Bamias, Aristotle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199819/ https://www.ncbi.nlm.nih.gov/pubmed/25336975 http://dx.doi.org/10.2147/OTT.S65522

Ejemplares similares

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2012)

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
por: Peeters, M, et al.
Publicado: (2013)

Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
por: Gavalas, Nikos G., et al.
Publicado: (2013)

The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling
por: Trachana, Sofia-Paraskevi, et al.
Publicado: (2016)

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
por: Lu, Jian-Feng, et al.
Publicado: (2012)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
por: Semrad, Thomas J, et al.
Publicado: (2019)

The role of high-dose chemotherapy in the treatment of testicular cancer
por: Karadimou, Alexandra, et al.
Publicado: (2010)

Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19
por: Liontos, Michalis, et al.
Publicado: (2020)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
por: Gavalas, Nikos G., et al.
Publicado: (2010)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
por: Rodolakis, Ioannis, et al.
Publicado: (2023)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment
por: Katsila, Theodora, et al.
Publicado: (2018)

386 corales = 386 chorales /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1968)

Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models
por: Wu, Benjamin, et al.
Publicado: (2011)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease
por: Fiste, Oraianthi, et al.
Publicado: (2022)

Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis
por: Karadimou, Alexandra, et al.
Publicado: (2010)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature
por: Liontos, Michalis, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
por: Karadimou, Alexandra, et al.
Publicado: (2011)

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
por: Chiu, Joanne W., et al.
Publicado: (2015)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
por: Bamias, Aristotle, et al.
Publicado: (2006)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Supportive medication in cancer during pregnancy
por: Zagouri, Flora, et al.
Publicado: (2020)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature
por: Papatheodoridi, Alkistis, et al.
Publicado: (2023)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vu0lk7u30n2fcd9uap3is7rvlb